Corporate Banner
Satellite Banner
Chromatography
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

NIH Funds University of Buffalo Drug Development Programme

Published: Thursday, October 31, 2013
Last Updated: Wednesday, November 13, 2013
Bookmark and Share
Grants totaling $1.86 M will fund new initiatives and partnerships and extend ongoing research programmes.

The University at Buffalo’s HIV Clinical Pharmacology Research Program has received several grants totaling $1.86 million from the National Institutes of Health (NIH) to fund new initiatives and partnerships in hepatitis C virus (HCV) drug development, nanomedicine research for tuberculosis (TB), pharmacogenomics of neurocognitive disorders for people with HIV/AIDS and to extend ongoing research projects.

The grant’s principal investigator and director is Gene D. Morse, PharmD, professor of pharmacy practice and associate director of UB’s New York State Center of Excellence in Bioinformatics and Life Sciences (CoE).

“The awards provide additional funding for the UB program while also expanding our HIV pharmacology research to include drug development for hepatitis C and tuberculosis,” says Morse.

Morse currently directs the AIDS Clinical Trials Group (ACTG) Clinical Pharmacology Core, a network of laboratories that includes pharmacology specialty laboratories (PSL) in the U.S., Thailand and Africa. Morse is also a member of the ACTG Executive Committee and a member of the ACTG Viral Hepatitis Transformative Science Group.

Some of the funds will be used to support UB’s HIV PSL, which has received continuous NIH support since 1987.

The UB PSL contributes to clinical pharmacology studies that investigate new drug treatments and designs and participates in drug interaction research during new drug development programs. The UB PSL operates a bioanalytical laboratory that develops and validates drug assays using innovative applications of liquid chromatography and mass spectrometry.

The new PSL collaborations in ACTG research include pharmaceutical partners such as U.S.-based Merck (Philadelphia), AbbVie (Chicago) and ITherX (San Diego).

A new, competitive funding supplement was also awarded to the PSL and includes UB’s Paras N. Prasad, SUNY Distinguished Professor of Chemistry, Physics, Medicine and Electrical Engineering and executive director of UB’s Institute for Lasers, Photonics and Biophotonics (ILPB).

This project will bring together the PSL’s bioanalysis techniques with ILPB’s extensive nanoparticle experience to create new nanomedicine formulations that incorporate drugs for tuberculosis using cell-targeted approaches. These approaches deliver medications directly to the site of TB infection in the lungs. The work will be conducted in the IPLB and the CoE’s new nanomedicine laboratory in collaboration with Jessica Reynolds, PhD, assistant professor from the Department of Medicine, Division of Allergy, Immunology and Rheumatology in the Clinical and Translational Research Center.

Funding is also included to continue the expansion of the UB PSL Precautionary and Prohibited Medications Database, a pharmacoinformatics database that identifies new clinical pharmacology studies of drug interactions among HIV, HCV and TB drugs during drug development.

It will also integrate new research data with an informatics utility that is based in the CoE’s Translational Pharmacology Research Core. This utility is used by NIH investigators for developing new treatment protocols that access the most current drug interaction data available, thus promoting the safety and protection of subjects who participate in these clinical studies.

The NIH funding additionally supports a new Mentored Research award for Qing Ma PhD, a research scientist in the CoE’s Translational Pharmacology Research Core and an investigator in the UB PSL. Ma has received a 5-year K08 award titled, “Genetic Risk of Neurocognitive Disorders in Patients with HIV Infection.”

The overall objective of Ma’s proposal is to provide advanced training in antiretroviral pharmacogenomics, related to pharmacokinetics and disease modeling in patients with HIV-associated neurocognitive disorders.

The research plan focuses on the development of a model system to improve risk and intervention assessments by integrating genetic data, pharmacokinetics and toxicity, to establish an individualized risk profile of HIV-associated neurocognitive disorders, one of the prevalent co-morbidities in treated individuals.   

Morse says he will serve as the primary mentor for Ma’s award, along with additional notable mentors Giovanni Schiffitto, MD, from the University of Rochester, David Haas, MD, from Vanderbilt and Scott Letendre, MD, from UCSD.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Structure of Essential Digestive Enzyme Uncovered
Using a powerful combination of techniques from biophysics to mathematics, researchers have revealed new insights into the mechanism of a liver enzyme that is critical for human health.
Why do Tomatoes Smell "Grassy"?
Researchers identify enzymes that convert the grassy smell of tomatoes into a sweeter scent.
Plasma Biomarkers for Breast Cancer Diagnosis
Plasma lipidomics profiling identified lipid biomarkers in distinguishing early-stage breast cancer from benign lesions.
A Mechanistic Tool for Studying Fungal Pathogens
This study presents an overview of lipid extraction, chromatographic separation and mass spectrometry employed in qualitative and quantitative sphingolipidomics in fungi.
Newborn Screening Test Developed For Rare, Deadly Neurological Disorder
Scientists have developed a new dried blood spot screening test for Niemann-Pick type C, with goal to speed diagnosis and treatment.
Grant to Fund Million Peaks Project
The European Research Council (ERC) has awarded a prestigious Advanced Grant to Prof. Peter Schoenmakers, Prof. Albert Polman and Prof. Huib Bakker, all three of whom work at the University of Amsterdam (UvA).
Altered Metabolism of Four Compounds Drives Glioblastoma Growth
Findings suggest new ways to treat the malignancy, slow its progression and reveal its extent more precisely.
Why Bearcats Smell Like Buttered Popcorn
Researchers pinpoint chemical compound that gives rare animal its popcorn-like scent.
Human Gut Microbiome Evolution
Westerners have a less-diverse gut microbiome compared to hunter-gatherers, but how and why these microbe collections diverged has largely remained a mystery.
Potential Diagnostic for Dengue Fever
Scientists from Colorado State University have explored the use of small molecules in patient serum for diagnosis of dengue fever and potentially predicting progression to the severe disease.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!